Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence
Sippel L, Hamblen J, Kelmendi B, Alpert J, Carpenter L, Grzenda A, Kraguljac N, McDonald W, Rodriguez C, Widge A, Nemeroff C, Schnurr P, Holtzheimer P, Biomarkers and Treatments T. Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence. American Journal Of Psychiatry 2024, 181: 1045-1058. PMID: 39616450, DOI: 10.1176/appi.ajp.20230950.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderStress disorderPathophysiology of posttraumatic stress disorderNon-trauma-focused psychotherapyTrauma-focused psychotherapySomatic treatment approachesEvidence-based treatmentsAntidepressant medicationSomatic treatmentsPsychiatric disordersSomatic interventionsTranscranial magnetic stimulationPsychotherapyMagnetic stimulationTreatment approachesDisordersRecommended first-line treatmentAdultsFirst-line treatmentMedicationMechanism of actionMonotherapy strategySalienceSpecific treatmentEvidenceMethylone is a rapid-acting neuroplastogen with less off-target activity than MDMA
Warner-Schmidt J, Stogniew M, Mandell B, Rowland R, Schmidt E, Kelmendi B. Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA. Frontiers In Neuroscience 2024, 18: 1353131. PMID: 38389788, PMCID: PMC10882719, DOI: 10.3389/fnins.2024.1353131.Peer-Reviewed Original ResearchPost-traumatic stress disorderTreatment of post-traumatic stress disorderFrontal cortexBrain areasMDMA-assisted psychotherapyEffects of methyloneMonoamine uptake inhibitorsNeuroplasticity-related genesMyelin-related genesAntidepressant-likeAnxiolytic effectsBrain substratesStress disorderPsychiatric disordersNeuropsychiatric disordersUptake inhibitorsBrain effectsAvailable pharmacotherapiesMDMAMDDEmotional learningMethyloneAmygdalaGene expression changesDisorders